FREMGANGSMÅDE TIL AT BESTEMME REAKTIVITET AF CANCER PÅ BEHANDLINGER MÅLRETTET MOD EPIDERMAL VÆKSTFAKTOR-RECEPTOR

• Main Authors: Sellers, William R, Bell, Daphne Winifred, Janne, Pasi Antero, Paez, Juan Guillermo, SORDELLA, Raffaella, Johnson, Bruce E, Settleman, Jeffrey E, Haber, Daniel A, MEYERSON, Matthew, Lynch, Thomas J
• Format: Patent
• Language: Danish
• Published: 29.07.2019
• Subjects: BEER; BIOCHEMISTRY; CHEMISTRY; COMPOSITIONS OR TEST PAPERS THEREFOR; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL ORENZYMOLOGICAL PROCESSES; DERIVATIVES THEREOF; ENZYMOLOGY; INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES; MEASURING; MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEICACIDS OR MICROORGANISMS; METALLURGY; MICROBIOLOGY; MUTATION OR GENETIC ENGINEERING; NUCLEIC ACIDS; NUCLEOSIDES; NUCLEOTIDES; ORGANIC CHEMISTRY; PHYSICS; PROCESSES OF PREPARING SUCH COMPOSITIONS; SPIRITS; SUGARS; TESTING; VINEGAR; WINE

The present invention is directed to a method for determining the responsiveness of cancer to an epidermal growth factor receptor (EGFR) treatment. In a preferred embodiment, the presence of at least one variance in the kinase domain of the erbB1 gene confers sensitivity to the tyrosine kinase inhibitor gefitinib. Thus, a diagnostic assay for these mutations will allow for the administration of gefitinib, erlotinib and other tyrosine kinase inhibitors to those patients most likely to respond to the drug.